Immunocore Holdings plc American Depositary Shares - IMCR STOCK NEWS

Immunocore reported first-quarter 2022 financials with revenues of £22.5 million ($29.6 million), driven by KIMMTRAK sales. Net product revenue from KIMMTRAK was £7.7 million ($10.1 million) as all early access patients transitioned to commercial supply. The company has a net cash position of approximately $271 million. KIMMTRAK received regulatory approvals in the U.S. and EU for metastatic uveal melanoma, positioning it as a standard treatment. The firm anticipates reporting data from its ImmTAC clinical candidates in the latter half of 2022.

insitro, a drug discovery firm utilizing machine learning, announced the formation of a scientific advisory board (SAB) comprising leading experts in various scientific fields. The SAB's expertise spans gene editing, molecular design, and diseases of the liver and central nervous system. The board will assist insitro in enhancing its technologies and drug development programs. CEO Daphne Koller emphasized the importance of diverse expertise in advancing drug discovery. Since its inception in 2018, insitro has raised over $700 million to drive its innovative research efforts.

Immunocore Holdings Plc (Nasdaq: IMCR) will present at the 21st Annual Needham Healthcare Conference on April 14, 2022, at 9:30 a.m. ET. The event will feature a fireside chat by company management, and the presentation will be available via a live webcast on Immunocore's website. Immunocore specializes in T cell receptor (TCR) bispecific immunotherapies targeting cancer and autoimmune diseases, with its leading product, KIMMTRAK, approved by the FDA for metastatic uveal melanoma, demonstrating significant survival benefits.

Immunocore Holdings announced that the European Commission has approved KIMMTRAK (tebentafusp) for treating unresectable or metastatic uveal melanoma, marking a historic achievement as the first TCR therapy approved in the EU.

KIMMTRAK demonstrated a significant overall survival benefit in a Phase 3 trial, with a median survival nearly 22 months and a hazard ratio of 0.51.

The approval follows a favorable opinion from the Committee for Medicinal Products for Human Use, and KIMMTRAK is now authorized across all EU member states.

Acacia Research Corporation (ACTG) reported strong financial results for the full year 2021, generating $149.2 million in net income, equating to $1.91 per diluted share. This performance was fueled by $76.0 million in revenue from its Intellectual Property segment and $116.1 million in realized gains primarily from its Life Sciences Portfolio. The company completed the acquisition of Printronix for $33 million, contributing $12.0 million to revenues. In 2022, it anticipates revenues between $13.0 million and $14.0 million for Q1, with a new $40 million stock repurchase program approved.

Avacta Group has appointed Dr. Christina Coughlin as a Non-executive Director, effective immediately. Dr. Coughlin is the CEO of CytoImmune Therapeutics and has extensive experience in biotechnology and pharmaceuticals, previously serving in leadership roles at Rubius Therapeutics and Immunocore. Her appointment is expected to enhance Avacta’s strategic direction in developing innovative cancer therapies using its Affimer® and pre|CISION™ platforms. The CEO and Chairman expressed confidence in her ability to contribute to the company's growth and clinical programs.

Immunocore Holdings Plc (Nasdaq: IMCR) announced its participation in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference scheduled for March 16, 2022, at 9:20 a.m. ET. The event will be available via live webcast on Immunocore’s website, with a replay offered for a limited time. Immunocore specializes in pioneering T cell receptor bispecific immunotherapies, aiming to treat diseases like cancer and autoimmune disorders. Its lead product, KIMMTRAK, has been approved by the U.S. FDA for treating metastatic uveal melanoma, a condition showing historical resistance to other therapies.

Immunocore reported full-year 2021 financial results, highlighting the FDA approval of KIMMTRAK® for unresectable or metastatic uveal melanoma, marking a significant milestone as the first TCR therapy approved for solid tumors. The company had a cash position of approximately $321 million as of December 31, 2021. Revenue for 2021 was $35.8 million, a decrease from the previous year, while total operating loss reached $182.5 million. The company plans to report data on its clinical candidates targeting PRAME and MAGE-A4 in 2022.

Immunocore announced a positive opinion from the CHMP recommending approval of KIMMTRAK® (tebentafusp) for treating unresectable or metastatic uveal melanoma (mUM) in Europe. If sanctioned by the EMA, KIMMTRAK would be the first approved therapy in this indication. The treatment showed significant overall survival benefits in clinical trials, with a hazard ratio of 0.51. KIMMTRAK has already received FDA approval in the U.S. Offering a new hope for patients, this therapy is part of Immunocore’s innovative T cell receptor treatment platform.